Weekly Investment Analysts’ Ratings Updates for Pharvaris (PHVS)

Pharvaris (NASDAQ: PHVS) has recently received a number of price target changes and ratings updates:

• 8/14/2026 – Pharvaris was given a new $60.00 price target by New Street Research.
• 8/14/2026 – Pharvaris had its “buy” rating reaffirmed by HC Wainwright.
• 8/13/2026 – Pharvaris had its price target raised by Guggenheim from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 8/13/2026 – Pharvaris was upgraded by HSBC Holdings plc to “overweight”.
• 8/13/2026 – Pharvaris had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Pharvaris had its price target raised by Royal Bank Of Canada from $51.00 to $52.00. They now have an “outperform” rating on the stock.
• 8/13/2026 – Pharvaris had its price target raised by Citizens Jmp from $74.00 to $75.00. They now have a “market outperform” rating on the stock.
• 7/18/2026 – Pharvaris was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Pharvaris had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Pharvaris is now covered by Wells Fargo & Company. They set an “overweight” rating and a $55.00 price target on the stock.
• 7/15/2026 – Pharvaris was upgraded by Wells Fargo & Company to “strong-buy”.
• 6/25/2026 – Pharvaris had its price target raised by Morgan Stanley from $41.00 to $46.00. They now have an “overweight” rating on the stock.

Insider Activity

In other Pharvaris news, insider Anne Lesage sold 27,872 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.48, for a total transaction of $988,898.56. Following the completion of the transaction, the insider directly owned 58,750 shares of the company’s stock, valued at $2,084,450. The trade was a 32.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. This trade represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 148,322 shares of company stock valued at $5,091,407.

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.